CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 34 enrolled
Drug / intervention
GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00725283
NCT00725283Phase 1Completed
CompareCT.gov

Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as Post-consolidation Therapy in Adult Patients With Acute Myeloid Leukemia

GlaxoSmithKline·interventional·Posted Jul 30, 2008·Updated Aug 7, 2018

In Brief

A Phase 1 clinical trial evaluating GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) for Leukaemia, Myelocytic, Acute. Completed, enrolled 34 participants across 10 sites in 2 countries.

Detailed Summary

This study is being done to evaluate the safety of a WT1 Antigen-Specific Cancer Immunotherapeutic (WT1 ASCI) as post-consolidation therapy in adult patients with WT1-positive Acute Myeloid Leukemia in first complete remission. It will also be analyzed to what extent this treatment induces an immune response, specific to the malignancy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukaemia, Myelocytic, Acute
CountriesFrance, United States
Collaborators--

Timeline

Phase 1CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 30, 2008
Enrollment StartOct 1, 2008
Primary CompletionJun 22, 2016
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 17.9 years ago

Interventions

GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)biological

Intramuscular administration